Latest News - Alnylam Pharmaceuticals
Top Corporates Hub
Alnylam Pharmaceuticals
Amgen's Q3 Earnings in the Cards: Here's What to Expect
29.10.2025 15:27
Amgen's Q3 results are on deck, with growth from newer drugs offset by biosimilar competition and pricing pressures.
How Recent Momentum and Analyst Upgrades Are Shaping Alnylam’s Evolving Investment Story
29.10.2025 14:10
Alnylam Pharmaceuticals has seen its consensus fair value price target rise slightly, moving from $451.68 to $467.94, as analysts gain renewed confidence in the company’s growth outlook. This uptick reflects optimism around the company’s product momentum and stronger revenue growth projections. Read on to discover how these evolving outlooks could shape Alnylam’s future and learn ways to stay informed as the story unfolds. What Wall Street Has Been Saying Recent analyst commentary on Alnylam...
Exploring Analyst Estimates for Alnylam (ALNY) Q3 Earnings, Beyond Revenue and EPS
28.10.2025 13:15
Evaluate the expected performance of Alnylam (ALNY) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Examining Alnylam Pharmaceuticals After Pipeline Breakthroughs and a 98% Stock Rally in 2025
27.10.2025 00:12
Thinking about what to do with Alnylam Pharmaceuticals stock right now? You are not alone. Every investor wants to know if the current price reflects real value, and it is not always obvious just by glancing at recent numbers. If you are looking for momentum, there is plenty to notice here: despite a dip of -3.8% last week, Alnylam is up an impressive 98.4% year-to-date and nearly 277% over five years. That kind of long-term trajectory commands attention and suggests that there may be forces...
Are You Looking for a Top Momentum Pick? Why Alnylam Pharmaceuticals (ALNY) is a Great Choice
15.10.2025 16:00
Does Alnylam Pharmaceuticals (ALNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy
15.10.2025 15:31
Rocket Pharmaceuticals surges as the FDA accepts its resubmitted BLA for Kresladi, a gene therapy targeting the rare LAD-I disorder.
Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock?
15.10.2025 14:16
Investors need to pay close attention to ALNY stock based on the movements in the options market lately.
Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX
15.10.2025 14:05
ATXS stock jumps 37% after agreeing to a $700 million cash-and-stock buyout by BioCryst, boosting the latter's HAE treatment pipeline.
What Catalysts Are Shaping the Evolving Narrative for Alnylam Pharmaceuticals?
15.10.2025 09:08
Alnylam Pharmaceuticals has seen a modest uptick in its fair value estimate, rising from $447.15 to $451.68 per share as a result of evolving analyst sentiment. This shift reflects heightened optimism, which is driven by strong commercial results and encouraging new clinical data. Read on to discover how you can stay informed about future changes in the Alnylam stock narrative. What Wall Street Has Been Saying Recent commentary from Wall Street analysts reveals a predominantly positive stance...
3 Stocks That Investors Might Be Undervaluing By An Estimated 15.7% To 46.8%
09.10.2025 11:37
As the S&P 500 and Nasdaq reach record highs, investors are keenly observing market movements amid ongoing economic developments such as the Federal Reserve's interest rate cuts and a prolonged government shutdown. In this buoyant yet uncertain environment, identifying undervalued stocks can be an effective strategy for those looking to capitalize on potential market inefficiencies.
Dow Jones Futures: Stocks Weather Oracle News; Tesla Skids On Cheap Model Y
08.10.2025 03:10
The major indexes fell Tuesday fell on Oracle AI fears, but not that much. Tesla stock retreated on a cheap Model Y that isn't so cheap.
Discover 3 Stocks Including ConnectOne Bancorp Priced Below Estimated Value
07.10.2025 11:37
As the U.S. stock market continues to reach new heights, with the Nasdaq and S&P 500 setting fresh closing records, investors are keenly observing opportunities amidst this bullish trend. In such an environment, identifying stocks priced below their estimated value can be a prudent strategy for those looking to potentially capitalize on market inefficiencies.
RNAi: The Benefits Of Shooting The Messenger
07.10.2025 11:05
Our RNAi play came from the understanding that personalization and the development of curated therapies are the future of medicine. Read more here...
3 Stocks That May Be Trading Below Estimated Value In October 2025
03.10.2025 11:37
As of October 2025, U.S. markets have been on an upward trajectory, with major indices like the Dow Jones Industrial Average and S&P 500 reaching fresh records despite concerns over a government shutdown. This resilient performance highlights the importance of identifying stocks that may be trading below their estimated value, offering potential opportunities for investors in a market setting characterized by record highs and ongoing economic uncertainties.
Alnylam Pharmaceuticals, Inc. (ALNY) Reports $492M Amvuttra Sales, Raises 2025 Revenue Guidance
30.09.2025 16:33
We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Alnylam Pharmaceuticals, Inc. is one of them. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a leading biotech company specializing in RNA interference (RNAi) therapeutics, is advancing treatments for rare and prevalent diseases, notably transthyretin amyloidosis (ATTR). Its flagship product, Amvuttra (vutrisiran), treats […]
New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
28.09.2025 15:13
CAMBRIDGE, Mass., September 28, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. Data from a post hoc analysis of the HELIOS
Is Alnylam Pharmaceuticals (ALNY) an Undervalued Stock?
25.09.2025 13:53
PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities in the second quarter of 2025 experienced significant volatility, as the steep sell-off that initiated at the beginning of the quarter ultimately led to a strong recovery. The S&P […]
Does Alnylam Pharmaceuticals (ALNY) Have the Potential to Generate Strong Long-Term Growth?
25.09.2025 13:18
Parnassus Investments, an investment management company, released the “Parnassus Mid Cap Growth Fund” second quarter 2025 investor letter. A copy of the letter can be downloaded here. The Fund (Investor Shares) returned 13.29% (net of fees) in the quarter, compared to the Russell Midcap Growth Index’s 18.20% return. Stock selection in the Industrials and Information […]
September 2025's Top Stocks Estimated To Be Trading Below Fair Value
25.09.2025 11:37
As of late September 2025, U.S. stock markets have experienced a downturn with major indices like the Dow Jones Industrial Average and the S&P 500 closing lower for two consecutive sessions, primarily due to declines in technology stocks despite an outperforming energy sector. Amidst these fluctuations and concerns over high valuations as noted by Federal Reserve Chair Jerome Powell, identifying undervalued stocks becomes crucial for investors seeking opportunities that may offer growth...
Alnylam Pharmaceuticals Insiders Sold US$12m Of Shares Suggesting Hesitancy
18.09.2025 15:00
Many Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) insiders ditched their stock over the past year, which may be of...